Compare Ginkgo Bioworks Holdings Inc (DNA) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs TORM plc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.55 (market cap $515.15M), while TORM plc trades at $28.6 (market cap $3.01B). The key difference: TORM plc is far larger — about 5.8× Ginkgo Bioworks Holdings Inc's market cap, and TORM plc pays a 9.59% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TRMD | |
|---|---|---|
Market Cap | $515.15M | $3.01B |
Sector | Health | Technology |
52-Week High | $16.14 | $34.87 |
52-Week Low | $5.48 | $18.77 |
Enterprise Value | $617.10M | $3.89B |
Dividend Yield | — | 9.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
TRMD trades at $29.49 with a neutral daily change. The stock shows strong fundamentals with a P/E of 8.57, net income margin of 24.41%, and ROE of 15.62%, though recent Q1 2026 EPS missed expectations. Technical indicators are bearish overall, with support at $28 and resistance at $30. Recent news highlights strong Q1 2026 results and a dividend of $0.70 per share.
The outlook is positive with 100% analyst buy ratings and robust cash flow, but risks include earnings volatility and market sentiment. The stock offers value through dividends and growth potential, yet investors should monitor earnings consistency and macroeconomic factors affecting the tanker market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
